Denrakibart Biosimilar Monoclonal Antibody (CCL17) for Research

Cat No.: GMP-Bios-INN-1159

Anti-CCL17/ABCD-2/SCYA17/TARC therapeutic antibody (Pre-made Denrakibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Denrakibart (development code GSK-3858279) is a monoclonal antibody targeting CCL17. It is developed by GSK for pain. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1159-1mg 1mg 3090
GMP-Bios-INN-1159-10mg 10mg
GMP-Bios-INN-1159-100mg 100mg
GMP-Bios-INN-1159-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Denrakibart biosimilar, Whole mAb, Anti-CCL17/ABCD-2/SCYA17/TARC Antibody: Anti-CCL17/C-C motif chemokine 17/CC chemokine TARC/Small-inducible cytokine A17 therapeutic antibody
INN Name Denrakibart
Target CCL17/ABCD-2/SCYA17/TARC
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G2
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Active
100% SI Structure None
99% SI Structure 5wk2:HL/5wk3:QP:SR:UT:WV
95-98% SI Structure None
Year Proposed 2024
Year Recommended na
Companies GSK
Conditions Approved na
Conditions Active Pain
Conditions Discontinued na
Production na
Development Tech na